Abstrato

The newest medicine: Chimeric antigen receptor T-Cell immunotherapy (CAR-T)

Daohong Chen

Recent approval of chimeric antigen receptor T-cell immunotherapy (CAR-T) for the clinical use represents a significant progress in the human defense war against cancer, and validates a novel bio-pharmaceutical platform that synergizes the strengths of adoptive cellular immunotherapy as well as molecular genetic engineering. With the curable efficacy for refractory B-cell malignancy, CAR-T is increasingly contributing to a paradigm shift toward immunotherapy in oncologic medicine and pharmaceutical innovation. Through optimization of the relevant bio-technological aspects with timely translation from science to medicine, CAR-T pipeline is expected to go beyond hematological application, to deliver additional therapeutic benefits to the patients with solid tumors.